In their study, rs1805110 (p.Ser15Phe) polymorphism was found to be present at a high frequency, i.e., in about 98.5% of examined cancer samples; however, the lack of case-control comparison made it impossible to confirm the association between rs1805110 (p.Ser15Phe) SNP occurrence and betaglycan down-regulation [17]. This evidence concerns the gene TGFBR3 and cancer.